Evaluation of Anti-Neuroinflammatory Activity of Isatin Derivatives in Activated Microglia.
Humans
Anti-Inflammatory Agents
/ pharmacology
Microglia
/ metabolism
Isatin
/ pharmacology
Neuroinflammatory Diseases
NF-kappa B
/ metabolism
Lipopolysaccharides
/ pharmacology
Nitric Oxide
/ metabolism
Tumor Necrosis Factor-alpha
/ metabolism
Nitric Oxide Synthase Type II
/ metabolism
Neuroprotective Agents
/ pharmacology
TNF-α
interleukin 6
isatin
microglia
neuroinflammation
nitric oxide
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
20 Jun 2023
20 Jun 2023
Historique:
received:
21
05
2023
revised:
14
06
2023
accepted:
19
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Neuroinflammation plays a crucial role in the progression of Alzheimer's disease and other neurodegenerative disorders. Overactivated microglia cause neurotoxicity and prolong the inflammatory response in many neuropathologies. In this study, we have synthesised a series of isatin derivatives to evaluate their anti-neuroinflammatory potential using lipopolysaccharide activated microglia as a cell model. We explored four different substitutions of the isatin moiety by testing their anti-neuroinflammatory activity on BV2 microglia cells. Based on the low cytotoxicity and the activity in reducing the release of nitric oxide, pro-inflammatory interleukin 6 and tumour necrosis factor α by microglial cells, the
Identifiants
pubmed: 37375437
pii: molecules28124882
doi: 10.3390/molecules28124882
pmc: PMC10301261
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Isatin
82X95S7M06
NF-kappa B
0
Lipopolysaccharides
0
Nitric Oxide
31C4KY9ESH
Tumor Necrosis Factor-alpha
0
Nitric Oxide Synthase Type II
EC 1.14.13.39
Neuroprotective Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Francisco de Vitoria University
ID : UFV2022-11
Organisme : Fundación Banco Sabadell and Fundación Familia Alonso
ID : FFA-2019
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Photochem Photobiol Sci. 2015 Nov;14(11):2064-73
pubmed: 26412034
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 15;851(1-2):51-70
pubmed: 16950667
Glia. 2019 Oct;67(10):1821-1841
pubmed: 31033014
Front Pharmacol. 2019 Sep 12;10:1008
pubmed: 31572186
Am J Physiol Cell Physiol. 2009 Sep;297(3):C742-9
pubmed: 19553566
Chem Cent J. 2011 Jul 01;5:37
pubmed: 21722377
ACS Chem Neurosci. 2021 Jul 7;12(13):2336-2346
pubmed: 34110771
J Clin Invest. 2017 Oct 2;127(10):3577-3587
pubmed: 28872464
Pharmacol Rep. 2013;65(2):313-35
pubmed: 23744416
Int J Mol Sci. 2020 Mar 27;21(7):
pubmed: 32230861
Toxicol Appl Pharmacol. 2019 Aug 15;377:114627
pubmed: 31202640
Pharmacol Rep. 2022 Aug;74(4):570-582
pubmed: 35594012
Pharmaceuticals (Basel). 2022 Feb 22;15(3):
pubmed: 35337070
Molecules. 2020 Sep 25;25(19):
pubmed: 32992673
Bioorg Chem. 2019 Aug;89:103021
pubmed: 31176854
Arch Pharm Res. 2003 Oct;26(10):778-84
pubmed: 14609123
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Molecules. 2022 May 31;27(11):
pubmed: 35684477
J Org Chem. 2014 Jun 6;79(11):4984-91
pubmed: 24787642
J Med Chem. 2023 Apr 27;66(8):5305-5331
pubmed: 37014977
Eur J Pharmacol. 2007 Feb 5;556(1-3):200-6
pubmed: 17141756
ACS Chem Neurosci. 2015 Sep 16;6(9):1591-9
pubmed: 26154082
Mini Rev Med Chem. 2021;21(9):1096-1112
pubmed: 33238872
ALTEX. 2009;26(2):83-94
pubmed: 19565166
Front Neurosci. 2021 Sep 24;15:742065
pubmed: 34630027
Eur J Med Chem. 2010 Mar;45(3):1068-77
pubmed: 20045221
Transl Neurodegener. 2020 Nov 26;9(1):42
pubmed: 33239064
Molecules. 2008 Sep 10;13(9):2126-35
pubmed: 18830145
Angew Chem Int Ed Engl. 2014 Oct 27;53(44):11960-4
pubmed: 25287788
Nat Rev Neurol. 2021 Mar;17(3):157-172
pubmed: 33318676